At present, pancreatic cancer patients, as well as patients with mesothelioma, non-small-cell lung cancer, and other advanced solid tumors, are being treated with the FAK inhibitor defactinib in combination with the programmed cell death protein-1 (PD-1) inhibitor pembrolizumab in early phase clinical trials [140, 141]. The gene discussed is PDCD1; the disease is mesothelioma.